Biotech leaders gather in San Sebastian for sold-out Bio€quity 2024

The great and the good of biotech descended on San Sebastian, Spain, for the influential Bio€quity Europe conference, one of the major dealmaking and networking events of the year. 

Despite inclement weather, the conference was sold out, allowing CEOs and investors to gather, network, partner and debate issues facing the biotech industry. 

Representatives of the Optimum team, including CEO Mary Clark, attended the event to catch up with our clients who were attending. 

Calliditas Therapeutics AB announced that its partner Everest Medicines has launched Nefecon in China. 

Calliditas Therapeutics AB on Tuesday announced that its partner Everest Medicines has launched Nefecon® in China. 

China, which is estimated to have up to 5 million patients suffering from the progressive autoimmune disease, IgA nephropathy (IgAN), has the highest prevalence of primary glomerular diseases in the world, with IgAN accounting for about 35% to 50% of cases with a biopsy proven incidence of over 100,000 patients per year. There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries. 

Calliditas will also be holding an in-person and virtual R&D day on Thursday, May 30, at Inderes Event Studio in Stockholm, beginning 3.00pm CET (9am ET). 

Publication in Nature Immunology outlining the contribution of B cells to anticancer immunosurveillance highlights Alchemab’s capabilities and potential to develop new cancer therapies 

Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, announced the publication of a peer reviewed article titled “Predictability of B cell clonal persistence and immunosurveillance in breast cancer” in the journal Nature Immunology. The senior author, Rachael Bashford-Rogers, is a co-founder of Alchemab and the paper was a collaboration between the Cancer Dynamics Group at The Institute of Cancer Research, London, (ICR), the University of Oxford, the University of Cambridge and Alchemab. 

Novo Holdings to acquire majority stake in Single Use Support 

Novo Holdings on Wednesday announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. 

Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10%, and Danaher which will retain 20% of the share capital. 

Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. 

Novo Nordisk Foundation grants up to €23 million to atherosclerosis prevention collaboration 

A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and encourage prevention. Denmark’s Novo Nordisk Foundation on Thursday said it had granted up to €23 million to cover the first 2.5 years of the REACT initiative. The initiative is expected to run for eight years in total.  

One in three people around the world die from cardiovascular disease, which is mainly caused by atherosclerosis. This makes atherosclerosis the leading cause of death globally.